{"prompt": "['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Survival', 'Non-Treatment', 'End of', 'FU', 'Screening', 'Treatment (Each Cycle)', 'Cycle Visit', 'Treatment', 'PTFUC', '(OS)d', 'Weekly', 'Within 7 Days', '(Day 8, 15, 22,', 'of Decision to', 'q6', 'q6', 'Day -21 to', 'Day', 'Day 1e', 'Day', 'Day', 'Day', 'Day 22', 'Day', 'Day', 'Day 1', '29,36)', 'Discontinue', 'Weeks', 'Weeks', 'Category', 'Description', 'Day -1', '-1', '(-3d)', '2', '8', '15', '(-3d)', '29', '36', '(=3d)', '(=3d)', 'Treatment', '(+1wk)', '(1wk)', 'Safety', 'Urinalysis', 'X', 'xk', 'X', 'X', 'X', 'Assessments', 'Pregnancy Test\u00b9', 'X', 'X', 'X', 'X', 'X', '(cont.)', 'Electrocardiogram', 'X', 'X', '(ECG)1', 'Echocardiogram\"', 'X', 'X', 'X', 'Performance Status', 'X', 'X', 'X', 'X', '(ECOG)', 'Fluid Retention', 'X', 'X', 'X', 'X', 'X', 'Questionnaire\u00b0', 'SAE/Adverse', 'SAE/', 'X', 'X', 'X', 'X', 'X', 'XP', 'XP', 'Events', 'Procedure', '-related', 'only', 'Concomitant', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'X', 'XP', 'XP', 'Medications', '121']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Survival', 'Non-Treatment', 'End of', 'FU', 'Screening', 'Treatment (Each Cycle)', 'Cycle Visit', 'Treatment', 'PTFUC', '(OS)d', 'Weekly', 'Within 7 Days', '(Day 8, 15, 22,', 'of Decision to', 'q6', 'q6', 'Day -21 to', 'Day', 'Day 1e', 'Day', 'Day', 'Day', 'Day 22', 'Day', 'Day', 'Day 1', '29,36)', 'Discontinue', 'Weeks', 'Weeks', 'Category', 'Description', 'Day -1', '-1', '(-3d)', '2', '8', '15', '(-3d)', '29', '36', '(=3d)', '(=3d)', 'Treatment', '(+1wk)', '(+1wk)', 'Treatment', 'rovalpituzumab', 'X', 'tesirine or placebo', 'dexamethasone or', 'X', 'X', 'placebo', 'Response', 'Disease/Response', 'X', 'X', 'X', 'XT', 'X', 'Assessment', 'Assessment', '(Radiographic', 'Imaging)', 'Central', 'X', 'X', 'X', 'XT', 'X', 'Radiographic', 'Assessment', 'Committee (CRAC)', 'Review', 'MRI/CT of the', 'Xt', 'Brain', 'Health Resource', 'X', 'X', 'X', 'X', 'X', 'Utilization', 'Patient Reported', 'X', 'X', 'X', 'X', 'X', 'Outcome (PRO\"', 'Survival Status', 'X', '122']['abbvie Rovalpituzumab Tesirine', 'M16-298 Protocol Amendment 4', 'EudraCT 2016-003503-64', 'Survival', 'Non-Treatment', 'End of', 'FU', 'Screening', 'Treatment (Each Cycle)', 'Cycle Visit', 'Treatment', 'PTFUC', '(OS)d', 'Weekly', 'Within 7 Days', '(Day 8, 15, 22,', 'of Decision to', 'q6', 'q6', 'Day -21 to', 'Day', 'Day 1e', 'Day', 'Day', 'Day', 'Day 22', 'Day', 'Day', 'Day 1', '29, 36)', 'Discontinue', 'Weeks', 'Weeks', 'Category', 'Description', 'Day -1', '-1', '(-3d)', '2', '8', '15', '(-3d)', '29', '36', '(=3d)', '(=3d)', 'Treatment', '(+1wk)', '(+1wk)', 'Pharmacoki', 'Pharmacokinetics', 'X', 'X', 'X', 'netic (PK),', '(PK), Anti-', 'Biomarkers,', 'therapeutic', 'and', 'Antibody (ATA),', 'Pharmacoge', 'and neutralizing', 'netic (PG)', 'antibodies (nAb)', 'Tumor Material at', 'X', 'Screening\"', 'Tumor Material at', 'X', 'X', 'Time of Disease', 'Progression f', 'Blood (plasma) for', 'X', 'X', 'X', 'XX', 'Inflammatory', 'Markers & ctDNAX', 'Blood (serum) for', 'X', 'X', 'X', 'XX', 'Tumor & Soluble', 'Markers*', 'Circulating Tumor', 'X', 'X', 'Cellsy', 'Pharmacogenetics\u00b2', 'X', 'X', 'Serosal Fluida', 'Cycle 1 Day 1 through 70 days after last blinded study treatment', '123']\n\n###\n\n", "completion": "END"}